Amgen has declared that new findings from its cardiovascular portfolio, which includes late-breaking results from the phase 3 VESALIUS-CV clinical trial of Repatha (evolocumab), will be showcased at the American Heart Association (AHA) Scientific
Takeda has completed its seven-year Phase 3 TIDES trial of QDENGA confirming that the vaccine provides lasting and reliable protection against dengue. The study, which also looked at the effects of a booster dose, showed that QDENGA maintains...
Fujifilm India has introduced its CAD EYE artificial intelligence endoscopy system at Fortis Hospital, Jaipur, marking a breakthrough moment for Rajasthan. This is the state’s first-ever AI-powered endoscopy installation, aimed at tackling the...
Bharat Biotech International Ltd has broadened its biologics portfolio to include the launch of Nucelion Therapeutics Pvt Ltd, a 100% owned contract research, development, and manufacturing organization (CRDMO) that focuses on the development
Novo Nordisk has made public the submission of an unsolicited proposal to Metsera, Inc. acquisition. Metsera is a biotech company with a strong portfolio of both early and development-stage incretin and non-incretin
You're standing in the toothpaste aisle at your local supermarket. One shelf has your regular adult toothpaste, the one with strong mint and whitening power.
Alkem Foundation, the Corporate Social Responsibility (CSR) arm of Alkem Laboratories Ltd., has announced a strategic collaboration with the Indian Institute of Technology Bombay
Johnson & Johnson MedTech, a cardiac arrhythmia treatment global leader, said that new clinical and real-world results of its VARIPULSE™ Platform in pulsed field ablation (PFA) of atrial fibrillation (AF) would be revealed at the Asia Pacific...
Roche announced that it has acquired the CE mark for Elecsys Dengue Ag, their high-throughput, fully-automated immunoassay system that helps the diagnosis of acute dengue virus infections.
Reflecting strong operational performance and consistent market momentum, Cipla Limited has reported a rise in both revenue and profitability for the quarter and half year ended September 30, 2025. The company’s results highlight continued growth in
, CDSCO.jpg "Fostering a Quality Culture in the Pharmaceutical Industry")